ReviewJournal of surgical oncology2019
Updates in adjuvant systemic therapy for melanoma.
Review in Journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recurrence Patterns for Regionally Metastatic Melanoma Treated in the Era of Adjuvant Therapy: A Systematic Review and Meta-Analysis.Annals of surgical oncology · 2023Pooled it
- Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.Nature medicine · 2023Trial
- Evaluating Variation in Lymph Node Sampling During Sentinel Lymph Node Biopsy for Melanoma.Annals of surgical oncology · 2025Article
- Completion of nodal dissection in cutaneous melanoma with metastatic sentinel nodes: Prognostic impact in a population-based cohort study.World journal of surgical oncology · 2025Article
- Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice.Annals of surgery · 2023Article
- International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers.Annals of surgery · 2023Article
- The Evolution of the Sentinel Node Biopsy in Melanoma.Life (Basel, Switzerland) · 2023Review
- Melanoma of the Scalp and Neck: A Population-Based Analysis of Survival and Treatment Patterns.Cancers · 2022Article
- Real-World Adherence to Nodal Surveillance for Sentinel Lymph Node-Positive Melanoma.Annals of surgical oncology · 2022Article
- Contrast mechanisms in pump-probe microscopy of melanin.Optics express · 2022Article
- Spatial biology analysis reveals B cell follicles in secondary lymphoid structures may regulate anti-tumor responses at initial melanoma diagnosis.Frontiers in immunology · 2022Article
- Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection.Annals of surgical oncology · 2021Article
- The Status of Adjuvant and Neoadjuvant Melanoma Therapy, New Developments and Upcoming Challenges.Targeted oncology · 2021Review
- Article
- Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas.Science advances · 2021Article
- Molecular Biomarkers for Melanoma Screening, Diagnosis and Prognosis: Current State and Future Prospects.Frontiers in medicine · 2021Review
- Identification of tumor mutation burden-related hub genes and the underlying mechanism in melanoma.Journal of Cancer · 2021Article
- Overexpression of RACK1 Predicts Poor Prognosis in Melanoma.Journal of Cancer · 2020Article
- ASO Author Reflections: Frequent Relapses Prior to the Start of Adjuvant Therapy in Stage IIIB/C Melanoma.Annals of surgical oncology · 2019Article
- Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis.Annals of surgical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
There has been a rapid increase in adjuvant therapies approved for treatment following surgical resection of stages III/IV melanoma. We review current indications for adjuvant therapy, which currently includes a heterogenous group of stages III and IV patients with melanoma. We describe several pivotal clinical trials of systemic immune therapies, targeted immune therapies, and adjuvant vaccine strategies. Finally, we discuss the evidence for selecting the most appropriate treatment regimen(s) for the individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.